Organon & Co. (OGN) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $3.00M; Additional Paid in Capital, Common StockUSD $199.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-548.00M; Retained Earnings (Accumulated Deficit)USD $1.35B.
- 2026-03-31: Common Stock, Value, IssuedUSD $3.00M; Additional Paid in Capital, Common StockUSD $186.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-539.00M; Retained Earnings (Accumulated Deficit)USD $1.25B.
- 2025-12-31: Common Stock, Value, IssuedUSD $3.00M; Additional Paid in Capital, Common StockUSD $167.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-527.00M; Retained Earnings (Accumulated Deficit)USD $1.11B.
- 2025-09-30: Common Stock, Value, IssuedUSD $3.00M; Additional Paid in Capital, Common StockUSD $159.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-574.00M; Retained Earnings (Accumulated Deficit)USD $1.32B.
Organon & Co. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00M | $199.00M | $-548.00M | $1.35B | $1.01B | 3 month · $13.00M 6 month · $32.00M | (m) |
| 2026-03-31 | $3.00M | $186.00M | $-539.00M | $1.25B | $903.00M | 3 month · $19.00M | (m) |
| 2025-12-31 | $3.00M | $167.00M | $-527.00M | $1.11B | $752.00M | 12 month · $59.00M | (m) |
| 2025-09-30 | $3.00M | $159.00M | $-574.00M | $1.32B | $906.00M | 3 month · $20.00M 9 month · $51.00M | (m) |
| 2025-06-30 | $3.00M | $139.00M | $-572.00M | $1.16B | $733.00M | 3 month · $9.00M 6 month · $31.00M | (m) |
| 2025-03-31 | $3.00M | $130.00M | $-617.00M | $1.03B | $542.00M | 3 month · $22.00M | (m) |
| 2024-12-31 | $3.00M | $108.00M | $-649.00M | $1.01B | $472.00M | 12 month · $83.00M | (m) |
| 2024-09-30 | $3.00M | $86.00M | $-571.00M | $975.00M | $493.00M | 3 month · $23.00M 9 month · $61.00M | (m) |
| 2024-06-30 | $3.00M | $63.00M | $-612.00M | $690.00M | $144.00M | 3 month · $14.00M 6 month · $38.00M | (m) |
| 2024-03-31 | $3.00M | $49.00M | $-577.00M | $573.00M | $48.00M | 3 month · $24.00M | (m) |
| 2023-12-31 | $3.00M | $25.00M | $-541.00M | $443.00M | $-70.00M | 12 month · $84.00M | (m) |
| 2023-09-30 | $3.00M | (m) | $-576.00M | $-16.00M | $-589.00M | 3 month · $25.00M 9 month · $59.00M | (m) |
| 2023-06-30 | $3.00M | (m) | $-533.00M | $-25.00M | $-555.00M | 3 month · $13.00M 6 month · $34.00M | (m) |
| 2023-03-31 | $3.00M | (m) | $-534.00M | $-206.00M | $-737.00M | 3 month · $21.00M | (m) |
| 2022-12-31 | $3.00M | $0.00 | $-564.00M | $-331.00M | $-892.00M | 12 month · $64.00M | (m) |
| 2022-09-30 | $3.00M | (m) | $-686.00M | $-383.00M | $-1.07B | 3 month · $15.00M 9 month · $41.00M | (m) |
| 2022-06-30 | $3.00M | (m) | $-589.00M | $-551.00M | $-1.14B | 3 month · $11.00M 6 month · $26.00M | (m) |
| 2022-03-31 | $3.00M | (m) | $-529.00M | $-724.00M | $-1.25B | 3 month · $15.00M | (m) |
| 2021-12-31 | $3.00M | (m) | $-513.00M | $-998.00M | $-1.51B | 12 month · $38.00M | $0.00 |
| 2021-09-30 | $3.00M | (m) | $-493.00M | $-1.13B | $-1.62B | 3 month · $15.00M 9 month · $23.00M | $0.00 |
| 2021-06-30 | $3.00M | (m) | $-464.00M | $-1.47B | $-1.93B | 3 month · $8.00M 6 month · $8.00M | $0.00 |
| 2021-03-31 | (m) | (m) | $-689.00M | (m) | $4.72B | (m) | (m) |
| 2020-12-31 | $0.00 | (m) | $-622.00M | $0.00 | $5.49B | (m) | $0.00 |
| 2020-09-30 | (m) | (m) | (m) | (m) | $7.33B | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $7.00B | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $7.03B | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $7.04B | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $6.35B | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |